<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        6-5115-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FOLOTYN 20MG/ML SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PRALATREXATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        15091.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAXTER ONCOLOGY GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAXTER ONCOLOGY GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MUNDIPHARMA MEDICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Pharmacotherapeutic group:</strong><br />Antineoplastic agents, antimetabolites</p><p><strong>Therapeutic indications:</strong><br />Folotyn is indicated in the treatment of adult patients with<br />peripheral Tcell lymphoma (nodal, extranodal and<br />leukaemic/disseminated) who have progressed and disease<br />progression after at least one prior treatment. The indication is<br />based on the response rate. No benefit in terms of progressionfree<br />survival or overall survival has been demonstrated.</p><p><strong>Properties/Effects</strong><br />ATC code: L01BA05</p><p><strong>Mechanism of action</strong><br />Pralatrexate is a folate antagonist which accumulates in tumour<br />cells by binding to folate transporter proteins, including Reduced<br />Folate-Carrier 1 (RFC-1), and as a substrate of folylpolyglutamyl<br />synthetase (FPGS), resulting in disruption of DNA synthesis and<br />subsequent tumour cell death via the inhibition of dihydrofolate<br />reductase (DHFR)<br />.</p><p><strong>Pharmacodynamic effect</strong><br />In vitro tests with various human lymphoma cells and in vivo<br />investigations with human xenograft tumour models showed<br />significant cytotoxicity and a reduction in tumour growth.</p><p><strong>Clinical efficacy</strong><br />In an open-label, uncontrolled, non-randomised study, 115<br />patients with peripheral T-cell lymphoma that progressed after at least one course of chemotherapy were treated with Folotyn 30 mg/m2 until the onset of disease progression or unacceptable toxicity. Of the 111 patients treated, 109 patients were evaluable<br />for efficacy.<br />The average age was 54 years and the median number of prior<br />therapies was three (1-12).<br />The primary efficacy endpoint was the overall response rate<br />(complete response (CR), complete response unconfirmed<br />(CRu) and partial response (PR)), as assessed in an independent<br />central review using the International Workshop Criteria<br />(IWC). This was 29% (CR+CRu 11%, PR 18%). The median<br />duration of response was 10.1 months.<br />Approximately two-thirds of patients (63%, n = 69) did not have<br />evidence of response to their most recent prior therapy before<br />entering the study. Of these 69 patients, 25% responded to<br />pralatrexate. Approximately a quarter of the patients (24%, n =<br />26) had not responded to any of the previous therapies. Of these 26 patients, 19% responded to pralatrexate.</p><p><strong>Pharmacokinetics</strong><br />Pralatrexate is a 1:1 racemic mixture of R- and S diastereomers<br />at the C10 chiral centre.</p><p><strong>Absorption</strong><br />The mean Cmax value for pralatrexate in PTCL patients is 5.8<br />&mu;g/ml and the mean total systemic exposure (AUC(0-&infin;)) is 268<br />&mu;g/ml∙min.</p><p><strong>Distribution</strong><br />In the pivotal study with PTCL patients, pralatrexate diastereomers<br />showed steady-state volumes of distribution of 105 l<br />(S-diastereomer) and 37 l (R-diastereomer) respectively.<br />The protein binding of pralatrexate is low (67%-86%).</p><p><strong>Metabolism</strong><br />Pralatrexate is not significantly metabolised by CYP450<br />isoenzymes or glucuronidases.</p><p><strong>Elimination</strong><br />The total systemic clearance of pralatrexate diastereomers is 417 ml/min. (S-diastereomer) and 191 ml/min. (R-diastereomer). The terminal elimination half-life of pralatrexate is 12 18 hours<br />(coefficient of variance (CV) = 62 120%). 31% of the<br />S-diastereomer and 38% of the R diastereomer are excreted in<br />urine. Elimination via the faeces has not been recorded.<br />Kinetics in specific patient groups<br />No investigations have been performed.</p><p>&nbsp;</p><p><strong>Preclinical data</strong><br />Pralatrexate was not mutagenic in standard in vitro and in vivo<br />mutagenicity assays (Ames test, chromosome aberration assay<br />in Chinese hamster ovary (CHO) cells and mouse micronucleus<br />assay). However, these tests may not reliably predict<br />genotoxicity for this class of compounds. Based on experience<br />with other antifolates, an increased risk for genotoxicity from<br />pralatrexate treatment cannot be excluded.<br />Carcinogenicity studies have not been performed with<br />pralatrexate.<br />No fertility studies have been performed. In rats and rabbits,<br />pralatrexate was embryotoxic and foetotoxic at intravenous<br />doses. In rats, pralatrexate caused a dose-dependent decrease<br />in foetal viability, manifested as an increase in late, early and total resorptions. There was also a dose dependent increase in post implantation loss. In rabbits, the observed toxicity manifested itself as early and total resorptions, post implantation loss and a decrease in the total number of live foetuses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Contraindications:</strong><br />Hypersensitivity to the active substance, pregnancy or lactation,<br />treatment with probenecid.</p><p><strong>Interactions:</strong><br />In vitro studies indicate that pralatrexate is not a substrate,<br />inhibitor, or inducer of cytochrome P450 (CYP450) isoenzymes<br />and thus has low potential for drug drug interactions during<br />metabolism by CYP450 isoenzymes (see &ldquo;Pharmacokinetics&rdquo;).<br />The co-administration of increasing doses of probenecid resulted in reduced clearance of pralatrexate (see &ldquo;Contraindications&rdquo;).<br />Pralatrexate did not significantly inhibit P-glycoprotein (P-gp),<br />breast cancer resistant protein (BCRP), organic cation<br />transporter 2 (OCT2), or organic anion transporters 1, 3 and<br />P1B3 (OAT1, OAT3 and OATP1B3). Pralatrexate was a weak<br />inhibitor of organic anion transporter P1B1 (OATP1B1, 35%<br />inhibition at 100 &mu;M) and multidrug resistance-associated protein 2 (MRP2; IC50 = 43.5 &mu;M). Since pralatrexate was found to be a potent inhibitor of multidrug resistance-associated protein 3 (MRP3; IC50 &lt; 0.3 &mu;M), a liver transporter implicated in transport of etoposide, teniposide, and methotrexate, caution is advised with concomitant use of these agents with pralatrexate.</p><p><br /><strong>Warnings and precautions:</strong><br />The pretreatment regimen of folic acid and vitamin B12 must be<br />strictly observed. The risk of myelosuppression and mucositis is<br />elevated without this treatment. The folic acid dosage may not be increased because this could impair the effect of the pralatrexate.<br />Patients should be asked at regular intervals about their<br />compliance. If they have failed to comply with instructions,<br />treatment should be stopped. The absolute neutrophil count<br />(ANC) should be &ge; 1,000/&mu;l, the platelet count should be &ge;<br />100,000/&mu;l for the first dose and &ge; 50,000/&mu;l for all subsequent<br />doses. Full blood cell counts should be monitored weekly for all<br />patients receiving pralatrexate. Serum chemistry tests, including renal and hepatic function, should be performed prior to the first and fourth dose of a given cycle, or more often if required.<br />Likewise, the mouth should be examined thoroughly before the<br />start of each dose of pralatrexate. Good oral hygiene (regular<br />mouthwashes, dental hygiene) should be maintained throughout treatment with pralatrexate.<br />If bone marrow suppression or mucositis occurs during treatment with pralatrexate, the dose should be adjusted in line with the platelet and neutrophil counts, fever and mucositis (see &ldquo;Posology and method of administration&rdquo;).<br />Regular inspection of the skin, and particularly areas affected by lymphoma, is essential during treatment. Serious and potentially life-threatening events, including exfoliative dermatitis,</p><p>skinnecrosis and toxic epidermal necrolysis (involving a fatal<br />outcome in some cases) have been observed. Most at risk are<br />patients with extensive skin involvement or a history of adverse<br />skin reactions. The first signs usually appear at an early stage of<br />treatment. The reactions may increase in severity with further<br />treatment. Treatment must be discontinued if severe<br />dermatological reactions (Grade 4) occur.<br />Caution should be used in the concomitant administration of<br />substances that are subject to renal tubular secretion (e.g.<br />NSAIDs, penicillins, omeprazole or pantoprazole), since these<br />my result in reduced clearance of pralatrexate.<br />Nephrotoxic medicinal products (e.g. aminoglycosides, loop<br />diuretics, platinum compounds, cyclosporine) should be avoided.<br />Etoposide, teniposide and methotrexate should not be<br />administered concurrently with pralatrexate because these<br />substances reduce the clearance of pralatrexate.<br />Trimethoprim/sulfamethoxazole has been reported in rare cases to increase bone marrow suppression in patients treated with methotrexate, presumably because of the increased antifolate effect. Caution is therefore advised during the concomitant use of these medicinal products with pralatrexate.<br />Men and women of childbearing age must use an effective<br />method of contraception during treatment with pralatrexate.<br />Pralatrexate may have genetically damaging effects.<br />Male patients are advised not to father a child during treatment and for up to 6 months thereafter. A barrier method or abstinence are recommended&nbsp;</p><p>There are no human data on the effect of pralatrexate on fertility. No fertility studies have been performed in animals. Due to the potential of antifolates to irreversibly affect fertility, patients should be offered appropriate counselling.</p><p><br /><strong>Pregnancy and Lactation:</strong><br /><strong>Pregnancy</strong><br />There are no data on the use of pralatrexate in pregnant women.<br />Studies in animals have shown reproductive toxicity (see<br />&ldquo;Preclinical data&rdquo;). Other antifolates of the same class have<br />caused teratogenic effects in humans. Folotyn should not be<br />used during pregnancy or in women of childbearing age who are not using contraception (see &ldquo;Contraindications&rdquo;). If the patient becomes pregnant while receiving pralatrexate, the patient should be informed of the possible risk to the foetus.<br /><strong>Lactation</strong><br />Folotyn should not be used in breast-feeding mothers (see<br />&ldquo;Contraindications&rdquo;), alternatively, breast-feeding should be<br />stopped beforehand.<br /><strong>Driving and using machines:</strong><br />Patients should be advised that they may experience fatigue,<br />blurred vision, or dizziness during treatment with Folotyn.<br />Patients should be advised against driving or using machines if<br />they experience any of these adverse reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Dosage/Administration</strong><br />Treatment should only be administered under the supervision of a physician experienced in the use of anticancer chemotherapy.<br />Folotyn is administered undiluted as an intravenous infusion over 3 5 minutes. The calculated dose should be aseptically<br />withdrawn into a syringe and administered via the side port of a<br />free flowing sodium chloride 9 mg/ml (0.9%) solution for injection intravenous line. Folotyn must not be administered by any other route of administration.</p><p><strong>Incompatibilities</strong><br />In the absence of compatibility studies, this medicinal product<br />must not be mixed with other medicinal products.<br />The recommended dose of pralatrexate is 30 mg/m2,<br />administered as an intravenous infusion over 3 5 minutes, once<br />weekly over a period of 6 weeks, followed by a 1 week rest period<br />and repetition of the 7 week cycle until disease progression or<br />unacceptable toxicity occurs.</p><p><br /><strong>Pre-treatment regimen</strong></p><p>1 mg vitamin B12 i.m. no more than 10 weeks prior to treatment and 1 mg folic acid daily for 10 days before the start of treatment.<br />As of the second dose, the i.m. vitamin B12 can be injected with<br />the pralatrexate (every 8-10 weeks). Oral treatment with folic acid at a dose of 1 mg per day should be continued during the full course of therapy, including during the treatment-free interval.<br /><strong>Blood test results</strong><br />The absolute neutrophil count (ANC) should be &ge; 1,000/&mu;l and<br />platelet count should be &ge; 100,000/&mu;l for the first dose and<br />&ge; 50,000/&mu;l for all subsequent doses. Full blood cell counts<br />should be monitored weekly for all patients receiving<br />pralatrexate. Serum chemistry tests, including renal and hepatic<br />function, should be performed prior to the start of the first and<br />fourth dose of a given cycle, or more often if required.<br />The dose should be omitted in the event of thrombocytopenia of &lt; 50,000/&mu;l or neutropenia of 500-1000/&mu;l that persists for 1<br />week; if it persists for 2 weeks, treatment should be continued at a reduced dose of 20 mg/m2. The dose should also be reduced to 20 mg/m2 in the event of the once-only recurrence of thrombocytopenia or neutropenia or in the event of neutropenic fever, and the use of G CSF or GM CSF is recommended.<br />Treatment should be discontinued if myelosuppression persists<br />for 3 weeks.<br /><strong>Mucositis</strong><br />Prior to initiating pralatrexate treatment, mucositis should not<br />exceed Grade 1. Severity of mucositis should be monitored<br />weekly for all patients receiving pralatrexate. In the event of<br />Grade 2 mucositis, the dose should be omitted, and the existing<br />dose can be continued if it improves to Grade &le; 1. However, if<br />Grade 2 mucositis returns or Grade 3 mucositis occurs, the dose<br />should be reduced to 20 mg/m2. Treatment should be<br />discontinued if Grade 4 occurs.</p><p><br /><strong>Other treatment-related toxicities</strong></p><p>In the event of treatment-related Grade 3 toxicity, the dose should be omitted and continued at 20 mg/m2 upon recovery to &le; Grade 2. Treatment should be discontinued in the event of Grade 4 toxicity.</p><p><br /><strong>Special dosage instructions</strong><br /><strong>Renal and hepatic impairment</strong><br />A third of the dose is excreted via the kidneys. Since no studies<br />have investigated patients with renal or hepatic impairment, no<br />recommended dosage can be given.<br /><strong>Elderly patients</strong><br />No dose adjustment is required in elderly patients with normal<br />renal function.<br /><strong>Paediatric population</strong><br />The safety and efficacy of Folotyn in paediatric patients have not been investigated. Patients under 18 years of age should not be treated with Folotyn.</p><p><strong>Overdose</strong><br />No information is available on the treatment of overdose of<br />Folotyn. The prompt administration of folinic acid, adequate<br />hydration and alkalinisation of the urine should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The most frequent adverse reactions were mucositis (68%,<br />Grade 3/4: 22%), thrombocytopenia (40%, Grade 3/4: 31%),<br />nausea (33%, Grade 3/4: 4%), anaemia (32%, Grade 3/4: 16%),<br />fatigue (30%, Grade 3/4: 6%), neutropenia (24%, Grade 3/4:<br />21%), epistaxis (23%, Grade 3/4: 0%), vomiting (21%, Grade 3/4:<br />2%) and constipation (21%, Grade 3/4: 0%).<br />The most serious adverse reactions were bone marrow<br />suppression (thrombocytopenia, neutropenia and anaemia),<br />mucositis, exfoliative dermatitis, toxic epidermal necrolysis and<br />tumour lysis syndrome.<br />Other common Grade 3/4 adverse reactions were skin ulcers,<br />infections, anorexia, dyspnoea, vomiting, nausea, pains and<br />fatigue.<br />Frequencies are defined as: very common (&ge; 1/10), common (&ge;<br />1/100 to &lt;1/10), uncommon (&ge; 1/1,000 to &lt;1/100), rare (&ge;<br />1/10,000 to &lt;1/1,000), very rare (&lt; 1/10,000), and not known<br />(cannot be estimated from available data).</p><p><br /><strong>Infections and infestations</strong><br /><strong>Common:</strong> Sepsis, pneumonia, bronchitis, urinary tract infection,<br />cellulitis, herpes zoster, abscess, infection, herpes virus<br />infection, upper respiratory infection, fungal infection, folliculitis<br /><strong>Uncommon: </strong>Clostridium difficile colitis, cytomegalovirus colitis<br />Neoplasms<br /><strong>Uncommon:</strong> Tumour lysis syndrome<br />Blood and lymphatic system disorders<br /><strong>Very common: </strong>Neutropenia (24%), leukopenia (11%),<br />thrombocytopenia (40%), anaemia (32%)<br /><strong>Common:</strong> Febrile neutropenia, pancytopenia, lymphopenia<br /><strong>Uncommon: </strong>Haemolytic anaemia<br />Metabolism and nutrition disorders<br />Very common: Anorexia (12%)<br /><strong>Common: </strong>Hyperkalaemia, hypokalaemia, dehydration,<br />hyperuricaemia, hyperglycaemia, hypomagnesaemia,<br />hypophosphataemia, weight loss<br />Uncommon: Hypercalcaemia<br />Psychiatric disorders<br /><strong>Common:</strong> Insomnia, anxiety<br />Nervous system disorders<br /><strong>Common:</strong> peripheral neuropathy, headache, dizziness,<br />paraesthesia, hypoaesthesia<br /><strong>Uncommon:</strong> Syncope, memory impairment<br />Eye disorders<br /><strong>Common: </strong>blurred vision, eye irritation, increased lacrimation,<br />ocular hyperaemia, eye pruritus<br /><strong>Uncommon: </strong>Reduced visual acuity, uveitis, photopsia, eyelid<br />ptosis, conjunctivitis<br />Ear and labyrinth disorders<br /><strong>Common: </strong>Tinnitus<br /><strong>Uncommon: </strong>Deafness, vertigo, hypoacusis<br />Cardiac disorders<br /><strong>Common: </strong>Tachycardia<br /><strong>Uncommon:</strong> Cardiorespiratory arrest, cardiomegaly, ejection<br />fraction reduced<br />Vascular disorders<br /><strong>Common:</strong> Hypotension<br /><strong>Uncommon:</strong> Venous thrombosis<br />Respiratory, thoracic and mediastinal disorders<br /><strong>Very common:</strong> Epistaxis (23%)<br /><strong>Common:</strong> Pleural effusion, dyspnoea, cough, pharyngolaryngeal<br />pain, dysphonia<br /><strong>Uncommon: </strong>Pneumonitis, pulmonary embolism, hypoxia,<br />pulmonary congestion, pleuritic pain<br />Gastrointestinal disorders<br />Very common: Mucositis (68%), vomiting (21%), diarrhoea<br />(17%), nausea (33%), constipation (21%)<br /><strong>Common: </strong>Abdominal pain, odynophagia, oral pain, dyspepsia,<br />rectal haemorrhage, dry mouth<br /><strong>Uncommon:</strong> Pancreatitis<br />Hepatobiliary disorders<br /><strong>Very common:</strong> elevated liver enzymes (ASAT 17%, ALAT 16%)<br /><strong>Common: </strong>Hepatosplenomegaly, hyperbilirubinaemia<br /><strong>Uncommon:</strong> Cholangitis<br />Skin and subcutaneous tissue disorders<br /><strong>Very common: </strong>Rash (11%)<br /><strong>Common:</strong> Skin ulcers, urticaria, pruritus, skin haemorrhage,<br />periorbital oedema, erythema, alopecia, dry skin<br />Uncommon: Exfoliative dermatitis, toxic dermatitis, night sweats<br /><strong>Not known: </strong>Toxic epidermal necrolysis<br />Musculoskeletal and connective tissue disorders<br /><strong>Very common</strong>: Musculoskeletal pain (11%)<br /><strong>Common:</strong> Back pain, neck pain, arthralgia, myalgia, muscle spasms<br /><strong>Uncommon: </strong>Costochondritis, joint swelling<br />Renal and urinary disorders<br /><strong>Common:</strong> Elevated blood creatinine<br /><strong>Uncommon: </strong>Renal failure<br />General disorders and administration site conditions<br /><strong>Very common: </strong>Pyrexia (19%), peripheral oedema (18%), fatigue (30%)<br /><strong>Common: </strong>Influenza-like illness, chest pain, chills, pain, asthenia,<br />facial oedema<br /><strong>Uncommon: </strong>Infusion-related reaction</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicinal product must not be used after the expiry date<br />(&ldquo;EXP&rdquo;) printed on the container.<br />The ready-to-use Folotyn solution for infusion contains no<br />preservatives and is intended for single use only. After<br />withdrawal of dose, discard any unused portion left in the vial.<br />Unused portions should not be saved for later administration.</p><p><strong>Special precautions for storage</strong><br />Store in the refrigerator (2-8&deg;0C) out of the reach of children.<br />Keep the vial in the outer carton in order to protect from light.<br />Unopened vials may be removed from the refrigerator and<br />stored at up to 30&deg;0C for a single period of up to 120 hours.</p><p><strong>Instructions for handling</strong><br />The rules for cytotoxic agents should be observed when<br />preparing and handling Folotyn.<br />Folotyn is a clear, yellow solution.<br />The vials should be inspected visually for particulate matter and<br />discolouration prior to administration. Vials exhibiting particulate matter or discolouration should not be used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Active substance:</strong> pralatrexate.<br /><strong>Excipients: </strong>Sodium chloride, sodium hydroxide, hydrochloric<br />acid, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                1 vial with 1 ml solution for infusion contains 20 mg pralatrexate
(a clear, yellow solution).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder :</strong><br />Mundipharma Medical Company, Hamilton/Bermuda, Basel<br />Branch (I.A.C of Mundipharma)<br />St. Alban-Rheinweg 74, CH-4020 Basel, Switzerland</p><p><br /><strong>Manufacturer:</strong><br />Baxter Oncology GmbH, Kantstra&szlig;e 2, 33790 Halle/Westfalen,<br />Germany<br />Packed by AndersonBrecon (UK) Ltd in United Kingdom</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Revised October 2013
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>.<img src="data:image/png;base64,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" alt="" width="210" height="618" vspace="0" hspace="0" border="0" style="width:210px;height:618px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                pralatrexate.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance: pralatrexate.
Excipients: Sodium chloride, sodium hydroxide, hydrochloric acid, water for injections.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 vial with 1 ml solution for infusion contains 20 mg pralatrexate.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of adult patients with peripheral T-cell lymphoma and disease progression after at least one prior<br />treatment. The indication is based on the response rate. No benefit in terms of progression-free survival or<br />overall survival has been demonstrated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should only be administered under the supervision of a physician experienced in the use of<br />anticancer chemotherapy.<br />The recommended dose of pralatrexate is 30 mg/m2<br />, administered as an intravenous infusion over<br />3-5 minutes, once weekly over a period of 6 weeks, followed by a 1 week rest period and repetition of the<br />7-week cycle until disease progression or unacceptable toxicity occurs.<br />Pre-treatment regimen<br />1 mg vitamin 812 Lm. no more than 10 weeks prior to treatment and 1 mg folic acid daily for 10 days before<br />the start of treatment. As of the second dose, the Lm. vitamin 812 can be injected with the pralatrexate (every<br />8-10 weeks). Oral treatment with folic acid at a dose of 1 mg per day should be continued during the full<br />course of therapy, including during the treatment-free interval.<br />Blood test results<br />The absolute neutrophil count (ANC) should be ~ 1,OOO/IJI and platelet count should be ~ 1OO,OOO/IJI for the<br />first dose and ~ 50,000/1J1 for all subsequent doses. Full blood cell counts should be monitored weekly for all<br />patients receiving pralatrexate. Serum chemistry tests, including renal and hepatic function, should be<br />performed prior to the start of the first and fourth dose of a given cycle, or more often if required.<br />The dose should be omitted in the event of thrombocytopenia of &lt; 50,000/1J1 or neutropenia of 500-1 OOO/IJI<br />that persists for 1 week; if it persists for 2 weeks, treatment should be continued at a reduced dose of<br />20 mg/m2<br />. The dose should also be reduced to 20 mg/m2 in the event of the once-only recurrence of<br />thrombocytopenia or neutropenia or in the event of neutropenic fever, and the use of G-CSF or GM-CSF is<br />recommended. Treatment should be discontinued if myelosuppression persists for 3 weeks.</p><p>&nbsp;</p><p>Mucositis<br />Prior to initiating pralatrexate treatment, mucositis should not exceed Grade 1. Severity of mucositis should<br />be monitored weekly for all patients receiving pralatrexate. In the event of Grade 2 mucositis, the dose<br />should be omitted, and the existing dose can be continued if it improves to Grade::; 1. However, if Grade 2<br />mucositis returns or Grade 3 mucositis occurs, the dose should be reduced to 20 mg/m2<br />. Treatment should<br />be discontinued if Grade 4 occurs.<br />Other treatment-related toxicities<br />In the event of treatment-related Grade 3 toxicity, the dose should be omitted and continued at 20 mg/m2<br />upon recovery to ::; Grade 2. Treatment should be discontinued in the event of Grade 4 tOXicity.<br />Special dosage instructions<br />Renal and hepatic impairment<br />A third of the dose is excreted via the kidneys. Since no studies have investigated patients with renal or<br />hepatic impairment, no recommended dosage can be given.<br />Elderly patients<br />No dose adjustment is required in elderly patients with normal renal function.<br />Paediatric population<br />The safety and efficacy of Fo(otyn in paediatric patients have not been investigated. Patients under 18 years<br />of age should not be treated with Folotyn.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, pregnancy or lactation, treatment with probenecid
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pretreatment regimen of folic acid and vitamin 812 must be strictly observed. The risk of<br />myelosuppression and mucositis is elevated without this treatment. The folic acid dosage may not be<br />increased because this could impair the effect of the pralatrexate. Patients should be asked at regular<br />intervals about their compliance. If they have failed to comply with instructions, treatment should be stopped.<br />The absolute neutrophil count (ANC) should be ~ 1,000/~1, the platelet count should be ~ 100,000/1-11 for the<br />first dose and ~ 50,000/~1 for all subsequent doses. Full blood cell counts should be monitored weekly for all<br />patients receiving praJatrexate. Serum chemistry tests, including renal and hepatic function, should be<br />performed prior to the first and fourth dose of a given cycle, or more often if required. Likewise, the mouth<br />should be examined thoroughly before the start of each dose of pralatrexate. Good oral hygiene (regular<br />mouthwashes, dental hygiene) should be maintained throughout treatment with pralatrexate.<br />If bone marrow suppression or mucositis occurs during treatment with pralatrexate, the dose should be<br />adjusted in line with the platelet and neutrophil counts, fever and mucositis (see &quot;Posology and method of<br />administration&quot;).</p><p>Regular inspection of the skin, and particularly areas affected by lymphoma, is essential during treatment.<br />Serious and potentially life-threatening events, including exfoliative dermatitis, skin necrosis and toxic<br />epidermal necrolysis (involving a fatal outcome in some cases) have been observed. Most at risk are<br />patients with extensive skin involvement or a history of adverse skin reactions. The first signs usually appear<br />at an early stage of treatment. The reactions may increase in severity with further treatment. Treatment must<br />be discontinued if severe dermatological reactions (Grade 4) occur.<br />Caution should be used in the concomitant administration of substances that are sUbject to renal tubular<br />secretion (e.g. NSAIDs, penicillins, omeprazole or pantoprazole), since these my result in reduced clearance<br />of pralatrexate.<br />Nephrotoxic medicinal products (e.g. aminoglycosides, loop diuretics, platinum compounds, cyclosporine)<br />should be avoided.<br />Etoposide, teniposide and methotrexate should not be administered concurrently with pralatrexate because<br />these substances reduce the clearance of pralatrexate.<br />Trimethoprim/sulfamethoxazole has been reported in rare cases to increase bone marrow suppression in<br />patients treated with methotrexate, presumably because of the increased antifolate effect. Caution is<br />therefore advised during the concomitant use of these medicinal products with pralatrexate.<br />Men and women of childbearing age must use an effective method of contraception during treatment with<br />pralatrexate. Pralatrexate may have genetically damaging effects. Male patients are advised not to father a<br />child during treatment and for up to 6 months thereafter. A barrier method or abstinence are recommended.<br />There are no human data on the effect of pralatrexate on fertility. No fertility studies have been performed in<br />animals. Due to the potential of antifolates to irreversibly affect fertility, patients should be offered appropriate<br />counselling.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No formal interaction studies have been performed.<br />In vitro studies indicate that pralatrexate is not a substrate, inhibitor, or inducer of cytochrome<br />P450 (CYP450) isoenzymes and thus has low potential for drug-drug interactions during metabolism by<br />CYP450 isoenzymes (see &quot;Pharmacokinetics&quot;).<br />The co-administration of increasing doses of probenecid resulted in reduced clearance of pralatrexate (see<br />&quot;Contraindications&quot;).<br />Pralatrexate did not significantly inhibit P-glycoprotein (P-gp), breast cancer resistant protein (8CRP),<br />organic cation transporter 2 (OCT2), or organic anion transporters 1, 3 and P1 83 (OAT1, OAT3 and<br />OATP183). Pralatrexate was a weak inhibitor of organic anion transporter P1 B1 (OATP1 81, 35% inhibition<br />at 100 I-JM) and multidrug resistance-associated protein 2 (MRP2; ICso =43.5 IJM). Since pralatrexate was<br />found to be a potent inhibitor of multidrug resistance-associated protein 3 (MRP3; ICso &lt; 0.3 IJM), a liver&nbsp;transporter implicated in transport of etoposide, teniposide, and methotrexate, caution is advised with<br />concomitant use of these agents with pralatrexate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />There are no data on the use of pralatrexate in pregnant women. Studies in animals have shown<br />reproductive toxicity (see &quot;Preclinical data&quot;). Other antifolates of the same class have caused teratogenic<br />effects in humans. F%tyn should not be used dUring pregnancy or in women of childbearing age who are<br />not using_contraception (see &quot;Contraindications&quot;). If the patient becomes pregnant while receiving<br />pralatrexate, the patient should be informed of the possible risk to the foetus.<br />Lactation<br />Folotyn should not be used in breast-feeding mothers (see &quot;Contraindications&quot;), alternatively, breast-feeding<br />should be stopped beforehand.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been performed. Patients should be advised that they may experience fatigue, blurred<br />vision, or dizziness during treatment with Folotyn. Patients should be advised against driving or using<br />machines if they experience any of these adverse reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequent adverse reactions were mucositis (68%, Grade 3/4: 22%), thrombocytopenia (40%, Grade<br />3/4: 31%), nausea (33%, Grade 3/4: 4%), anaemia (32%, Grade 3/4: 16%), fatigue (30%, Grade 3/4: 6%),<br />neutropenia (24%, Grade 3/4: 21%), epistaxis (23%, Grade 3/4: 0%), vomiting (21%, Grade 3/4: 2%) and<br />constipation (21%, Grade 3/4: 0%).<br />The most serious adverse reactions were bone marrow suppression (thrombocytopenia, neutropenia and<br />anaemia), mucositis, exfoliative dermatitis, toxic epidermal necrolysis and tumour lysis syndrome.<br />Other common Grade 3/4 adverse reactions were skin ulcers, infections, anorexia, dyspnoea, vomiting,<br />nausea, pains and fatigue.<br />Frequencies are defined as: very common (~ 1/10), common (::?: 1/100 to &lt;1/10),<br />uncommon (::?: 1/1,000 to &lt;1/100), rare (~1/10,000 to &lt;1/1,000), very rare &laquo; 1/10,000), and not<br />known (cannot be estimated from available data).<br />Infections and infestations<br />Common: Sepsis, pneumonia, bronchitis, urinary tract infection, cellulitis, herpes zoster, abscess, infection,<br />herpes virus infection, upper respiratory infection, fungal infection, folliculitis<br />Uncommon: Clostridium difficile colitis, cytomegalovirus colitis</p><p>Uncommon: Tumour lysis syndrome<br />Blood and lymphatic system disorders<br />Vel}&#39; common: Neutropenia (24%), leukopenia (11 %), thrombocytopenia (40%), anaemia (32%)<br />Common: Febrile neutropenia, pancytopenia, lymphopenia<br />Uncommon: Haemolytic anaemia<br />Metabolism and nutrition disorders<br />Vel}&#39; common: Anorexia (12%)<br />Common: Hyperkalaemia, hypokalaemia, dehydration, hyperuricaemia, hyperglycaemia, hypomagnesaemia,<br />hypophosphataemia, weight loss<br />Uncommon: Hypercalcaemia<br />Psychiatric disorders<br />Common: Insomnia, anxiety<br />Nervous system disorders<br />Common: peripheral neuropathy, headache, dizziness, paraesthesia, hypoaesthesia<br />Uncommon: Syncope, memory impairment<br />Eye disorders<br />Common: blurred vision, eye irritation, increased lacrimation, ocular hyperaemia, eye pruritus<br />Uncommon: Reduced visual acuity, uveitis, photopsia, eyelid ptosis, conjunctivitis<br />Ear and labyrinth disorders<br />Common: Tinnitus<br />Uncommon: Deafness, vertigo, hypoacusis<br />Cardiac disorders<br />Common: Tachycardia<br />Uncommon: Cardiorespiratory arrest, cardiomegaly, ejection fraction reduced<br />Vascular disorders<br />Common: Hypotension<br />Uncommon: Venous thrombosis<br />Respiratol}&#39;, thoracic and mediastinal disorders<br />Vel}&#39; common: Epistaxis (23%)<br />Common: Pleural effusion, dyspnoea, cough, pharyngolaryngeal pain, dysphonia<br />Uncommon: Pneumonitis, pulmonary embolism, hypoxia, pulmonary congestion, pleuritic pain<br />Gastrointestinal disorders<br />Vel}&#39; common: Mucositis (68%), vomiting (21 %), diarrhoea (17%), nausea (33%), constipation (21 %)<br />Common: Abdominal pain, odynophagia, oral pain, dyspepsia, rectal haemorrhage, dry mouth</p><p>Uncommon: Pancreatitis<br />Hepatobiliary disorders<br />Very common: elevated liver enzymes (ASAT 17%, ALAT 16%)<br />Common: Hepatosplenomegaly, hyperbilirubinaemia<br />Uncommon: Cholangitis<br />Skin and subcutaneous tissue disorders<br />Very common: Rash (11 %)<br />Common: Skin ulcers, urticaria, pruritus, skin haemorrhage, periorbital oedema, erythema, alopecia, dry skin<br />Uncommon: Exfoliative dermatitis, toxic dermatitis, night sweats<br />Not known: Toxic epidermal necrolysis<br />Musculoskeletal and connective tissue disorders<br />Very common: Musculoskeletal pain (11 %)<br />Common: Back pain, neck pain, arthralgia, myalgia, muscle spasms<br />Uncommon: Costochondritis, joint swelling<br />Renal and urinary disorders<br />Common: Elevated blood creatinine<br />Uncommon: Renal failure<br />General disorders and administration site conditions<br />Very common: Pyrexia (19%), peripheral oedema (18%), fatigue (30%)<br />Common: Influenza-like illness, chest pain, chills, pain, asthenia, facial oedema<br />Uncommon: Infusion-related reaction</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No experience of pralatrexate overdosage has been acquired.<br />No information is available on the treatment of overdose of F%tyn. The prompt administration of folinic acid,<br />adequate hydration and alkalinisation of the urine should be considered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: L01BA05<br />Mechanism of action<br />Pralatrexate is a folate antagonist which accumulates in tumour cells by binding to folate transporter proteins,<br />including Reduced Folate-Carrier 1 (RFC-1), and as a substrate of folylpolyglutamyl synthetase (FPGS),<br />resulting in disruption of DNA synthesis and subsequent tumour cell death via the inhibition of dihydrofolate<br />reductase (DHFR).</p><p>&nbsp;</p><p>Pharmacodynamic effect</p><p>In vitro tests with various human lymphoma cells and in vivo investigations with human xenograft tumour<br />models showed significant cytotoxicity and a reduction in tumour growth.<br />Clinical efficacy<br />In an open-label, uncontrolled, non-randomised study, 115 patients with peripheral T-cell lymphoma that<br />progressed after at least one course of chemotherapy were treated with Folotyn 30 mg/m2 until the onset of<br />disease progression or unacceptable toxicity. Of the 111 patients treated, 109 patients were evaluable for<br />efficacy.<br />The average age was 54 years and the median number of prior therapies was three (1-12).<br />The primary efficacy endpoint was the overall response rate (complete response (CR), complete response<br />unconfirmed (CRu) and partial response (PR)), as assessed in an independent central review using the<br />International Workshop Criteria (IWC). This was 29% (CR+CRu 11 %, PR 18%). The median duration of<br />response was 10.1 months.<br />Approximately two-thirds of patients (63%, n ::: 69) did not have evidence of response to their most recent<br />prior therapy before entering the stUdy. Of these 69 patients, 25% responded to pralatrexate. Approximately<br />a quarter of the patients (24%, n ::: 26) had not responded to any of the previous therapies. Of these<br />26 patients, 19% responded to pralatrexate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pralatrexate is a 1:1 racemic mixture of R- and S-diastereomers at the C10 chiral centre.<br />Absorption<br />The mean Cmax value for pralatrexate in PTCL patients is 5.8 j.Jg/ml and the mean total systemic exposure<br />(AUC(o__&raquo;) is 268 j.Jg/ml&middot;min.<br />Distribution<br />In the pivotal study with PTCL patients, pralatrexate diastereomers showed steady-state volumes of<br />distribution of 105 I (S-diastereomer) and 37 I (R-diastereomer) respectively.<br />The protein binding of pralatrexate is low (67%-86%).<br />Metabolism<br />Pralatrexate is not significantly metabolised by CYP450 isoenzymes or glucuronidases.<br />Elimination<br />The total systemic clearance of pralatrexate diastereomers is 417 mllmin. (S-diastereomer) and 191 mllmin.<br />(R-diastereomer). The terminal elimination half-life of pralatrexate is 12-18 hours (coefficient of variance (CV)<br />= 62-120%). 31% of the S-diastereomer and 38% of the R diastereomer are excreted in urine. Elimination via<br />the faeces has not been recorded.<br />Kinetics in specific patient groups<br />No investigations have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pralatrexate was not mutagenic in standard in vitro and in vivo mutagenicity assays (Ames test, chromosome<br />aberration assay in Chinese hamster ovary (CHO) cells and mouse micronucleus assay). However, these<br />tests may not reliably predict genotoxicity for this class of compounds. Based on experience with other<br />antifolates, an increased risk for genotoxicity from pralatrexate treatment cannot be excluded.<br />Carcinogenicity studies have not been performed with pralatrexate.<br />No fertility studies have been performed. In rats and rabbits, pralatrexate was embryotoxic and foetotoxic at<br />intravenous doses. In rats, pralatrexate caused a dose-dependent decrease in foetal Viability, manifested as<br />an increase in late, early and total resorptions. There was also a dose dependent increase in post<br />implantation loss. In rabbits, the observed toxicity manifested itself as early and total resorptions, post<br />implantation loss and a decrease in the total number of live foetuses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Excipients: Sodium chloride, sodium hydroxide, hydrochloric acid, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility stUdies, this medicinal product must not be mixed with other medicinal<br />products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This medicinal product must not be used after the expiry date ("EXP") printed on the container.
The ready-to-use Folotyn solution for infusion contains no preservatives and is intended for single use only.
After withdrawal of dose, discard any unused portion left in the vial. Unused portions should not be saved for
later administration.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the refrigerator (2-8&deg;C) out of the reach of children.<br />Keep the vial in the outer carton in order to protect from light.<br />Unopened vials may be removed from the refrigerator and stored at up to 30&deg;C for a single period of up to<br />120 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1 vial of 20 mg/1 ml solution for infusion [A]</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The rules for cytotoxic agents should be observed when preparing and handling Folotyn.<br />Folotyn is a clear, yellow solution.&nbsp;The vials should be inspected visually for particulate matter and discolouration prior to administration. Vials exhibiting particulate matter or discolouration should not be used</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mundipharma Medical Company, Hamilton/Bermuda, Basel branch.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>